和记体育

Be the most trusted biotech company

2022-07-19

Henlius Denosumab Biosimilar HLX14 Received Clinical Trial Approval in Australia for the Phase 3 MRCT
2022-07-06

First Subject Dosed in China on Phase 1/2 Trial of Henlius' Anti-PD-L1×TIGIT Bispecific Antibody
2022-06-30

Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53 IND Approved by NMPA
2022-06-28

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
2022-06-23

Henlius’ Self-developed Asymmetric Multichain Bispecific Antibody Cell Line Leading the Industry with High Titer and Purity
2022-06-21

Henlius’ Songjiang First Plant Received QP Declaration of Its GMP Equivalence to EU GMP
2022-06-20

Henlius Attends BIO 2022
2022-06-17

First Subject Dosed in Phase 3 MRCT of Denosumab Biosimilar HLX14
2022-06-13

Henlius and Organon Enter into a License and Supply Agreement for Henlius’ Two Biologics in ex-China Countries

1
2
3
4
5
6
7